Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000944324 | SCV001090293 | likely benign | not provided | 2024-10-06 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002427362 | SCV002681217 | likely benign | Hereditary cancer-predisposing syndrome | 2019-05-28 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Center for Genomic Medicine, |
RCV002465812 | SCV002761124 | likely benign | not specified | 2025-03-04 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000944324 | SCV005376342 | uncertain significance | not provided | 2023-10-16 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge; Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this variant does not alter splicing |
Prevention |
RCV003895733 | SCV004711967 | likely benign | MSH3-related disorder | 2023-06-06 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |